Mumbai, Melbourne, July 17, 2025:: Global pharma major Lupin Limited (Lupin) today announced that the API manufacturing facility of its wholly owned subsidiary, Lupin Manufacturing Solutions (LMS), in Dabhasa, Gujarat, has received the Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA), Australia’s medicines and medical devices regulator. LMS offers pharmaceutical CDMO services and is engaged in the manufacturing and supply of APIs.

“We are pleased to have received the GMP certification from TGA for our Dabhasa facility. This reflects the high standard of our manufacturing practices and expertise of our team at Dabhasa,” said Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions. “As we continue to expand our global footprint, we remain focused on quality, compliance, and the highest standards of operational integrity, setting new benchmarks in the CDMO space.”

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn  https://www.linkedin.com/company/lupin

About Lupin Manufacturing Solutions
Lupin Manufacturing Solutions (LMS) is a wholly owned subsidiary of Lupin, a trusted name in the pharmaceutical industry with a legacy of fulfilling unmet patient needs for over five decades. LMS specializes in manufacturing and supplying high-quality, cost-effective Active Pharmaceutical Ingredients (APIs) and are the “Partner of Choice” in the Contract Development and Manufacturing Operations (CDMO) space for Drug substance.
https://www.lupin.com/LMS/

For further information or queries please contact:
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com